Delayed Onset of Cardiac Allograft Vasculopathy by Induction Therapy Using Anti-thymocyte Globulin

Journal of Heart and Lung Transplantation

Volumn 27, Issue 6, 2008, Pages 603-609

  Zhang, Ruoyu ^a   Haverich, Axel ^a   Strüber, Martin ^a   Simon, Andre ^a   Bara, Christoph ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OKT 3; PREDNISOLONE; STEROID; THYMOCYTE ANTIBODY;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BACTERIAL INFECTION; CANCER INCIDENCE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYCOSIS; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION;

AGED; ANTILYMPHOCYTE SERUM; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUROMONAB-CD3; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 44049104354     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.02.016     Document Type: Article

References (32)

1. Adamson R., Obispo E., Dychter S., et al. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience. Transplant Proc 30 (1998) 1107-1109
2. Hosenpud J.D., Bennett L.E., Keck B.M., et al. The registry of the International Society of Heart and Lung Transplantation: fourteenth official report-1997. J Heart Lung Transplant 16 (1997) 691-712
3. Luyt C.E., Drobinski G., Dorent R., et al. Prognosis of moderate coronary artery lesions in heart transplant patients. J Heart Lung Transplant 22 (2003) 130-136
4. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 17 (1998) 744-753
5. Johnson M.R. Transplant coronary disease: non-immunologic risk factors. J Heart Lung Transplant 11 (1992) 124-132
6. Caforio A., Tona F., Fortina A.B., et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 4 (2004) 962-970
7. Cotts W.G., and Johnson M.R. The challenge of rejection and cardiac allograft vasculopathy. Heart Fail Rev 6 (2001) 227-240
8. Jimenez J., Kapadia S.R., Yamani M.H., et al. Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant 20 (2001) 393-398
9. Mehra M.R., Ventura H.O., Chambers R.B., et al. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. J Heart Lung Transplant 16 (1997) 743-751
10. Ventura H.O., White C.J., Ramee S.R., et al. Coronary angioscopy in the diagnosis of graft coronary artery disease in heart transplant recipients. J Heart Lung Transplant 10 (1991) 488
11. Sarris G.E., Moore K.A., Schroeder J.S., et al. Cardiac transplantation: the Stanford experience in the cyclosporine era. J Thorac Cardiovasc Surg 108 (1994) 240-251
12. Starnes V.A., Oyer P.E., Stinson E.B., et al. Prophylactic OKT3 used as induction therapy for heart transplantation. Circulation 80 suppl (1989) III-79-III-83
13. Kirklin J.K., Bourge R.C., White-Williams C., et al. Prophylactic therapy for rejection after cardiac transplantation: a comparison of rabbit antithymocyte globulin and OKT3. J Thorac Cardiovasc Surg 99 (1990) 716-724
14. Carrier M., White M., Perrault L.P., et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 18 (1999) 1218-1223
15. Billingham M.E., Cary N.R., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 9 (1990) 587-593
16. Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant 9 (2005) 373-380
17. Chin C., Pittson S., Luikart H., et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 80 (2005) 477-481
18. Haddad M., Alghofaili F.S., Fergusson D.A., et al. Induction immunosuppression after heart transplantation: monoclonal vs. polyclonal antithymoglobulins. Is there a difference?. Interactive Cardiovasc Thorac Surg 4 (2005) 415-419
19. Flaman F., Zieroth S., Rao V., et al. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 25 (2006) 1358-1362
20. Mullen J.C., Oreopoulos A., Lien D.C., et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 26 (2007) 504-510
21. Hammond E.H., Yowell R.L., Nunoda S., et al. Vascular (humoral) rejection in heart transplantation: pathologic observation and clinical complications. J Heart Transplant 8 (1989) 430-443
22. Fishbein M.C., and Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol 19 (2004) 166-169
23. Bonnefoy-Berard N., and Revillard J.P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15 (1996) 435-442
24. Russell P.S., Chase C.M., Winn H.J., and Colvin R.B. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am J Pathol 144 (1994) 260-274
25. Russell P.S., Chase C.M., Winn H.J., and Colvin R.B. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 152 (1994) 5135-5141
26. Russell P.S., Chase C.M., Winn H.J., and Colvin R.B. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant atherosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 64 (1997) 1531-1536
27. Russell P.S., Chase C.M., Sykes M., et al. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol 167 (2001) 5731-5740
28. Heidecke C.D., Araujo J.L., Kupiec-Weglinski J.W., et al. Lack of evidence for an active role for natural killer cells in acute rejection of organ allografts. Transplantation 40 (1985) 441-444
29. Uehara S., Chase C.M., Kitchens W.H., et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol 175 (2005) 3424-3430
30. Anguita M., Lopez-Rubio F., Arizon J.M., et al. Repetitive nontreated episodes of grade 1B or 2 acute rejection impair long-term cardiac graft function. J Heart Lung Transplant 14 (1995) 452-460
31. Labarrere C.A., Nelson D.R., and Park J.W. Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol 16 (2001) 110-117
32. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 (2006) 869-879